Want to see IL:NRGN full AI Analyst Report?
Top Page
Nrgene
(TASE:NRGN)
Select Model
Select Model
Rating:47Neutral
Price Target:
112.00
▼(-19.60% Downside)
Action:Reiterated
Date:09/06/26
The score is held back primarily by very weak technicals (price well below key moving averages with negative MACD and extremely low RSI) and loss-making fundamentals implied by a negative P/E. Offsetting these risks, financial performance shows improvement in 2025 with a sharp revenue rebound, much better gross margin, and a move to positive operating cash flow, but profitability and free-cash-flow durability remain unproven.
Positive Factors
Revenue rebound
The sharp 2025 revenue rebound shows renewed commercial traction after several years of contraction. If the improvement persists, a larger customer and project base could provide operating leverage and support investment in the Genomics Suite and related services.
Negative Factors
Persistent operating losses
Despite stronger revenue and gross margin, Nrgene remains deeply loss-making at both net and operating levels. Continued losses weaken retained capital and show that the current scale and cost structure have not yet produced sustainable earnings power.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The sharp 2025 revenue rebound shows renewed commercial traction after several years of contraction. If the improvement persists, a larger customer and project base could provide operating leverage and support investment in the Genomics Suite and related services.
Read all positive factors
Nrgene (NRGN) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪15.10M
Dividend YieldN/A
Average Volume (3M)7.79K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth115.63%
EPS Growth60.19%
CountryIL
Employees23
SectorGeneral
Sector StrengthN/A
IndustrySoftware - Application
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,327,785
10 Day Avg. Volume12,535
30 Day Avg. Volume7,787
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.94
Price to Sales (P/S)2.64
P/FCF Ratio116.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nrgene Business Overview & Revenue Model
Company Description
NRGene Technologies Ltd is an AI-powered genomics firm that designs sophisticated computational tools and advanced algorithms, serving clients globally across North America, Europe, the Middle East, Africa, and Asia Pacific. The company provides s...
How the Company Makes Money
Nrgene’s monetization is centered on providing access to its bioinformatics/genomics software and related services to customers that need genomic assembly and analysis capabilities. Key revenue streams typically include (1) software licensing/subs...
Nrgene Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
63
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.25M | 3.17M | 1.29M | 2.00M | 3.16M | 4.46M |
| Gross Profit | 1.92M | 1.92M | 267.00K | 901.00K | 1.71M | 2.46M |
| EBITDA | -1.98M | -965.00K | -2.69M | -4.53M | -5.59M | -8.37M |
| Net Income | -2.58M | -1.50M | -3.36M | -5.24M | -6.21M | -8.34M |
Balance Sheet | ||||||
| Total Assets | 7.12M | 9.54M | 6.00M | 10.79M | 17.30M | 26.36M |
| Cash, Cash Equivalents and Short-Term Investments | 3.18M | 5.30M | 1.37M | 6.45M | 12.28M | 22.87M |
| Total Debt | 145.02K | 181.00K | 288.00K | 797.00K | 1.61M | 3.34M |
| Total Liabilities | 4.66M | 5.13M | 2.00M | 3.57M | 5.04M | 8.68M |
| Stockholders Equity | 2.51M | 4.31M | 3.96M | 7.21M | 12.26M | 17.68M |
Cash Flow | ||||||
| Free Cash Flow | -511.43K | 72.00K | -5.19M | -5.58M | -7.83M | -6.67M |
| Operating Cash Flow | 268.11K | 855.00K | -3.56M | -3.91M | -6.12M | -5.57M |
| Investing Cash Flow | 364.72K | 455.00K | -1.30M | -1.27M | 12.47M | -14.83M |
| Financing Cash Flow | 42.23K | 1.53M | -317.00K | -410.00K | -2.46M | 27.59M |
Nrgene Technical Analysis
Positive
139.30
Price Trends
228.32
Positive
251.70
Negative
Market Momentum
4.23
Negative
71.57
Negative
99.75
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NRGN, the sentiment is Positive. The current price of 139.3 is below the 20-day moving average (MA) of 231.63, below the 50-day MA of 228.32, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 4.23 indicates Negative momentum. The RSI at 71.57 is Negative, neither overbought nor oversold. The STOCH value of 99.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:NRGN.
Nrgene Peers Comparison
UnderperformOutperform
Sector (55)
IL:NRGN
Nrgene
113.30
-170.60
-60.09%
IL:MTRX
Matrix
11,050.00
-404.57
-3.53%
IL:TECT
Tectona
190.80
-150.70
-44.13%
IL:MPRS
Mediprss Pu
57.20
5.30
10.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.